Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics

Inga-Marie Schaefer1, Christopher Dm Fletcher1, Jason L Hornick1

  • 1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Insights

Loss of histone H3K27 trimethylation (H3K27me3) is a specific marker for malignant peripheral nerve sheath tumors. This epigenetic alteration may indicate tumor progression and potential sensitivity to targeted therapies.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Pathology

Background:

  • Malignant peripheral nerve sheath tumors (MPNSTs) pose diagnostic challenges, especially in sporadic cases.
  • Inactivation of Polycomb Repressive Complex 2 (PRC2) is frequent in MPNSTs, leading to loss of H3K27me3.
  • H3K27me3 loss is a potential diagnostic marker for MPNSTs.

Purpose of the Study:

  • To validate immunohistochemistry for H3K27me3 as a diagnostic marker for MPNSTs.
  • To assess the correlation between H3K27me3 loss and tumor grade and type.
  • To investigate the role of PRC2 inactivation in MPNST progression.

Main Methods:

  • Immunohistochemistry for H3K27me3 was performed on 100 MPNSTs and 200 other spindle cell neoplasms.
  • MPNSTs included sporadic, neurofibromatosis type 1-associated, radiation-associated, and epithelioid subtypes.
  • Comparison of H3K27me3 expression across different tumor types and grades.

Main Results:

  • 51% of MPNSTs showed complete H3K27me3 loss; 6% had heterogeneous expression.
  • H3K27me3 loss was observed in 49% of sporadic, 70% of NF1-associated, and 100% of radiation-associated MPNSTs.
  • Complete H3K27me3 loss increased with tumor grade (29% low, 59% intermediate, 83% high grade).
  • Four unclassified postradiation sarcomas also showed H3K27me3 negativity; all other mimics were positive.
  • H3K27me3 loss demonstrated high specificity for MPNSTs.

Conclusions:

  • Loss of H3K27me3 is a highly specific marker for MPNSTs, aiding in diagnosis.
  • PRC2 inactivation and subsequent H3K27me3 loss may occur during MPNST progression to higher grades.
  • H3K27me3 loss could guide epigenetic-based targeted therapies for MPNST patients.